专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06790441B1 Sertoli cells as biochambers 失效
标题翻译： Sertoli细胞作为生物体
公开(公告)号：US06790441B1
公开(公告)日：2004-09-14
申请号：US09593629
申请日：2000-06-13
申请人： Don F. Cameron , Paul R. Sanberg , Samuel Saporta , Joelle J. Hushen
发明人： Don F. Cameron , Paul R. Sanberg , Samuel Saporta , Joelle J. Hushen
IPC分类号： A01N6500
CPC分类号： C12N5/0677 , A61K35/12 , C12N5/0619 , C12N2502/246
摘要： According to the present invention, there is provided a biological chamber system having a biochamber defined by outer walls of Sertoli cells. Also provided is a transplantation facilitator including a biochamber. A method of making biochambers by co-culturing facilitator cells and therapeutic cells and then aggregating the facilitator celes is also provided. Also provided is a method of transplanting cells by incorporating transplant cells into a biochamber and transplanting the biochamber containing the transplant cells.
摘要翻译：根据本发明，提供了一种具有由Sertoli细胞的外壁限定的生物室的生物室系统。还提供了包括生物室的移植促进剂。还提供了通过共培养促进细胞和治疗细胞然后聚集辅助细胞来制备生物体的方法。还提供了通过将移植细胞并入生物室并移植含有移植细胞的生物室来移植细胞的方法。

2. 发明授权

US6037175A Method and media for enhancing cryopreservation of cells 失效
标题翻译：用于增强细胞冷冻保存的方法和培养基
公开(公告)号：US6037175A
公开(公告)日：2000-03-14
申请号：US615039
申请日：1996-03-12
申请人： Don F. Cameron , Paul R. Sanberg , Cesario V. Borlongan , Samuel Saporta
发明人： Don F. Cameron , Paul R. Sanberg , Cesario V. Borlongan , Samuel Saporta
IPC分类号： A01N1/02 , A61K35/12 , C12N5/071 , C12N5/0793
CPC分类号： C12N5/0683 , A01N1/0226 , C12N5/0619 , A61K2035/122 , A61K35/12 , C12N2502/246
摘要： A method of enhancing the viability of cryopreserved cells is culturing Sertoli cells in media to produce preconditioned media and adding the preconditioned media to the cells to be cryopreserved. The cells are then cryopreserved. Alternatively, a method of enhancing the viability of cryopreserved cells is co-culturing Sertoli cells and cells to be cryopreserved in media and cryopreserving both.
摘要翻译：提高冷冻保存细胞活力的方法是在培养基中培养Sertoli细胞以产生预处理的培养基，并将预处理的培养基加入待冷冻保存的细胞中。然后将细胞冷冻保存。或者，提高冷冻保存细胞的存活力的方法是共培养Sertoli细胞和细胞以在培养基中冷冻保存并冷冻保存两者。

3. 发明授权

US5942437A Method and media for enhancing viability maturation, and cryopreservation of cells 失效
标题翻译：用于增强活力成熟和细胞冷冻保存的方法和培养基
公开(公告)号：US5942437A
公开(公告)日：1999-08-24
申请号：US799108
申请日：1997-02-11
申请人： Paul R. Sanberg , Agneta Othberg , Don F. Cameron , Samuel Saporta , Cesario V. Borlongan
发明人： Paul R. Sanberg , Agneta Othberg , Don F. Cameron , Samuel Saporta , Cesario V. Borlongan
IPC分类号： A01N1/02 , A61K35/12 , C12N5/071 , C12N5/0793 , A01N63/00
CPC分类号： C12N5/0683 , A01N1/0226 , C12N5/0619 , A61K2035/122 , A61K35/12 , C12N2502/246
摘要： A method to increase viability, number, survival and maturation of cells for transplantation or cryopreservation by culturing the cells with Sertoli cells or with sertoli-cell conditioned media (SCM) prior to transplantation (pre-culturing) or cryopreservation.
摘要翻译：在移植（预培养）或低温保存之前通过用Sertoli细胞或sertoli细胞条件培养基（SCM）培养细胞来增加用于移植或冷冻保存的细胞的活力，数量，存活和成熟的方法。

4. 发明申请

US20070065422A1 Induction of immune tolerance by sertoli cells 审中-公开
标题翻译：通过sertoli细胞诱导免疫耐受
公开(公告)号：US20070065422A1
公开(公告)日：2007-03-22
申请号：US11524003
申请日：2006-09-20
申请人： Don Cameron , Nagwa Dajani , Rania Shamekh , Samuel Saporta
发明人： Don Cameron , Nagwa Dajani , Rania Shamekh , Samuel Saporta
IPC分类号： A61K48/00
CPC分类号： C12N5/0683 , A61K35/34 , A61K2035/122
摘要： The subject invention pertains to methods to enhance the therapeutic effects of cell therapy in various diseases and disorders. More particularly, the present invention provides methods of inducing systemic immune tolerance, thereby reducing or eliminating the need for systemic immunosuppression, by administering isolated Sertoli cells to an individual in need of treatment, wherein the isolated Sertoli cells are administered to the individual prior to or during administration of the therapy, e.g., cellular therapy.
摘要翻译：本发明涉及增强细胞治疗在各种疾病和病症中的治疗效果的方法。更具体地，本发明提供了诱导全身免疫耐受的方法，从而减少或消除了对全身性免疫抑制的需要，通过向需要治疗的个体施用分离的Sertoli细胞，其中将分离的Sertoli细胞施用于个体在在治疗期间，例如细胞治疗。

5. 发明申请

US20080160614A1 STABLE DIFFERENTIATION OF ADULT STEM CELLS 有权
标题翻译：成熟干细胞的稳定分化
公开(公告)号：US20080160614A1
公开(公告)日：2008-07-03
申请号：US11966427
申请日：2007-12-28
申请人： Samuel Saporta , Elise Spencer , Rania Shamekh
发明人： Samuel Saporta , Elise Spencer , Rania Shamekh
IPC分类号： C12N5/02 , C12N5/00
CPC分类号： C12N5/0619 , C12N2506/02 , C12N2533/32
摘要： A method of differentiating adult stem cells, such as those derived from a teratocarcinoma cell line, the Ntera2/D1 clone (NT2). The developed cells exhibit a stable neurotransmitter phenotype without the required use of growth factors or retinoic acid in differentiation process, which may be difficult to completely remove during commercial production. An identification of specific neurotransmitters is possible in these differentiated NT2-derived neurons (NT2-N) after 30 days in culture or 30 days survival in vivo. The invention includes a method to stably differentiate neuronal stem/precursor cells to a neuronal phenotype for use in cell replacement therapy for neurodegenerative disease, stroke or spinal cord injury. At least four different types of neurons are produced from this method of differentiation: dopaminergic, cholinergic, GABAergic and glutaminergic. Additionally, since the cells are a cancer stem cell prior to differentiation, they may serve as a model system for developing anti-cancer therapies aimed at the cancer stem cell, rather than the more differentiated daughter cell.
摘要翻译：一种区分成体干细胞的方法，例如衍生自畸胎癌细胞系的那些，Ntera2 / D1克隆（NT2）。发育的细胞在分化过程中不需要使用生长因子或视黄酸，表现出稳定的神经递质表型，这在商业生产过程中可能难以完全去除。在培养30天后，在体内存活30天，这些分化的NT2来源的神经元（NT2-N）可以鉴定特异性神经递质。本发明包括将神经元干/前体细胞稳定地分化为用于神经变性疾病，中风或脊髓损伤的细胞替代疗法中的神经元表型的方法。从这种分化方法产生至少四种不同类型的神经元：多巴胺能，胆碱能，GABA能和谷氨酸能。此外，由于细胞是分化前的癌干细胞，它们可以用作开发针对癌症干细胞的抗癌疗法的模型系统，而不是更加分化的子细胞。

6. 发明授权

US08778680B2 Stable differentiation of NT2 cells 有权
标题翻译： NT2细胞稳定分化
公开(公告)号：US08778680B2
公开(公告)日：2014-07-15
申请号：US11966427
申请日：2007-12-28
申请人： Samuel Saporta , Elise Spencer , Rania Shamekh
发明人： Samuel Saporta , Elise Spencer , Rania Shamekh
IPC分类号： A61K35/30 , G01N33/48
CPC分类号： C12N5/0619 , C12N2506/02 , C12N2533/32
摘要： A method of differentiating adult stem cells, such as those derived from a teratocarcinoma cell line, the Ntera2/D1 clone (NT2). The developed cells exhibit a stable neurotransmitter phenotype without the required use of growth factors or retinoic acid in differentiation process, which may be difficult to completely remove during commercial production. An identification of specific neurotransmitters is possible in these differentiated NT2-derived neurons (NT2-N) after 30 days in culture or 30 days survival in vivo. The invention includes a method to stably differentiate neuronal stem/precursor cells to a neuronal phenotype for use in cell replacement therapy for neurodegenerative disease, stroke or spinal cord injury. At least four different types of neurons are produced from this method of differentiation: dopaminergic, cholinergic, GABAergic and glutaminergic. Additionally, since the cells are a cancer stem cell prior to differentiation, they may serve as a model system for developing anti-cancer therapies aimed at the cancer stem cell, rather than the more differentiated daughter cell.
摘要翻译：一种区分成体干细胞的方法，例如衍生自畸胎癌细胞系的那些，Ntera2 / D1克隆（NT2）。发育的细胞在分化过程中不需要使用生长因子或视黄酸，表现出稳定的神经递质表型，这在商业生产过程中可能难以完全去除。在培养30天后，在体内存活30天，这些分化的NT2来源的神经元（NT2-N）可以鉴定特异性神经递质。本发明包括将神经元干/前体细胞稳定地分化为用于神经变性疾病，中风或脊髓损伤的细胞替代疗法中的神经元表型的方法。从这种分化方法产生至少四种不同类型的神经元：多巴胺能，胆碱能，GABA能和谷氨酸能。此外，由于细胞是分化前的癌干细胞，它们可以用作开发针对癌症干细胞的抗癌疗法的模型系统，而不是更加分化的子细胞。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式